Nutraceutical (diet, probiotics, prebiotics, synbiotics), pharmaceutical (antibiotics, e.g., rifaximine) or surgical (e.g., bariatric surgery) interventions can modify NAFLD phenotype [77], through changes in BA composition that affect signaling through FXR and possibly other BA receptors [20,82,83]. Here, NR1H4 is linked to metabolic dysfunction-associated steatotic liver disease.